Aims: People with type 1 diabetes (PwT1D) use either multiple daily injections (MDI) or continuous subcutaneous insulin infusion (CSII), but CSII adoption is limited. Therefore, this study examines how the transition from MDI to CSII, utilizing an innovative modular micropump system, affects treatment satisfaction and metabolic outcomes.

Methods: 50 CSII-naive Argentinian PwT1D were enrolled in a multicenter, prospective, single-armed study for the Accu-Chek® Solo micropump system (ACS). Outcome: Change in diabetes treatment satisfaction (assessed by the Diabetes Technology Questionnare (DTQ) and HbA1c after 13 weeks as well as 1 and 2 years. Linear mixed models were utilized for analyses, with respective baseline scores as fixed effects and site as random effect.

Results: The change score of the “Impact and satisfaction” part of the DTQ was 113.37 ± 16.74 (mean ± SD, p < 0.0001) after 13 weeks, 111.42 ± 14.42 (p < 0.0001) after 1 year and 107.78 ± 16.14 after 2 years (p = 0.0005) (90 = non-change score). The following mean DTQ change scores were measured after 13 weeks / 1 / 2 years: 3.81 ± 0.61 / 3.79 ± 0.52 / 3.73 ± 0.63 for “diabetes distress and burden”, 3.96 ± 0.68 / 3.98 ± 0.60 / 3.81 ± 0.79 for “hypoglycemia fear, worry and behavior”, 3.56 ± 0.71 / 3.53 ± 0.52 / 3.43 ± 0.67 for “device acceptance and satisfaction” (1 = much worse, 5 = much better). The mean HbA1c decreased from 8.20 % ± 1.34 to 7.93 % ± 1.19 (-0.28 %pt, p = 0.0375) after 13 weeks, 7.87 % ± 1.26 (-0.37 %pt, p = 0.0467) after 1 year and 7.95 % ± 1.32 (-0.28 %pt, p = 0.1716) after 2 years. Two events of severe hypoglycemia and one diabetic ketoacidosis (DKA) were reported during 32248 device days.

Conclusion: Transitioning from MDI to CSII with ACS resulted in a significant enhancement of participants' treatment satisfaction and HbA1c levels after 13 weeks and 1 year, and an improvement was sustained for up to year 2. This implies that using ACS diminishes the disease burden for people with T1D.

Disclosure

A. Dain: Research Support; Roche Diabetes Care. K. Scheibner: None. S. Moceri: Employee; Roche Diabetes Care. N. Dagenbach: Employee; Roche Diabetes Care. C. Vulcano: Employee; Roche Diabetes Care. G. Vogt: Employee; Roche Diabetes Care. J. Best: Employee; Roche Diabetes Care. T.J. Etter: None.

© 2024 by the American Diabetes Association
2024
Readers may use this article as long as the work is properly cited, the use is educational and not for profit, and the work is not altered. More information is available at http://www.diabetesjournals.org/content/license.